Backs FY26 adjusted EBITDA view $29M-$33M. “The underlying strength of our transformed economic model is finally shining through as we began generating operating cash flow this quarter. Our quality of earnings and cash conversion will only improve in the coming quarters as we clear the last remaining Passenger divestiture transaction-related outflows,” said Will Heyburn, Co-CEO and CFO. “Our Clinical division showed especially strong sequential growth, with Gross Profit up nearly 30% versus Q4 2025, driven by a combination of new customer wins, a rebound in overall industry organ donors and continued industry mix shift towards third-party surgical recovery and NRP, where Strata is a market leader.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTA:
- Strata Critical Medical management to meet virtually with Lake Street
- Cathie Wood Sells Strata Critical Medical (SRTA), but Top Analysts See 120% Upside in This Penny Stock. Here’s Why
- Cathie Wood Buys the Dip in GeneDx (WGS); Wall Street Sees 142% Upside
- Cathie Wood’s $240M OpenAI Bet: ARK Adds OpenAI Exposure to ETFs Ahead of IPO
- Craig-Hallum bullish on Strata Critical Medical, initiates with a Buy